Clinicopathological Predictors of Recurrence in Uterine Sarcomas-A Narrative Review
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This review identifies clinical, histological, and molecular factors predicting recurrence in uterine sarcomas like leiomyosarcomas. Further research is needed to refine risk stratification and personalize patient care.
Area Of Science
- Gynecologic Oncology
- Pathology
- Genetics
Background
- Sarcomas are rare, diverse malignant tumors originating from mesenchymal tissues.
- They exhibit varied histopathology, clinical courses, and treatment responses.
- Uterine sarcomas include leiomyosarcomas, carcinosarcomas, and endometrial stromal sarcomas.
Purpose Of The Study
- To clarify clinicopathological and molecular predictors of recurrence in specific uterine sarcomas.
- To enhance understanding for improved clinical knowledge and patient care.
- To guide consultation practices and treatment strategies.
Main Methods
- Comprehensive structured narrative review of literature.
- Searched PubMed/MEDLINE, Embase, Cochrane Library, and Scopus.
- Included articles published up to 31 March 2025.
Main Results
- Summarized evidence on clinical, histological, and molecular predictors of recurrence and poor prognosis.
- Identified stage, grade, tumor size, and molecular biomarkers as high-risk parameters.
- Noted contradictory results in existing data, highlighting the need for further research.
Conclusions
- Next-generation sequencing aids in identifying women at increased risk of recurrence and adverse prognosis.
- Stratifying risk requires understanding clinical, histological, and molecular factors.
- This knowledge is essential for effective consultation, management, and individualized care.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...